Publications by authors named "F Trillsch"

Claim this Profile
D
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
P Harter, F Trillsch, A Okamoto, A Reuss, J-W Kim

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancer.
Juliane Reichenbach, Juliana Schmid, Sophia Hierlmayer, Tingyu Zhang, Ilaria Piga, Fabian Trillsch

iScience· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trial.
Sven Mahner, Fabian Trillsch, Janice S Kwon, Sarah E Ferguson, Paul Bessette

Int J Surg· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of FLYWCH1 as a regulator of platinum-resistance in epithelial ovarian cancer.
Tabea L Fullstone, Helene Rohm, Till Kaltofen, Sophia Hierlmayer, Juliane Reichenbach, Fabian Trillsch

NAR Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.
Anna Reischer, Alexandra Leutbecher, Björn Hiller, Enrico Perini, Kieron White, Fabian Trillsch

Cancer Immunol Immunother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis